Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6876)	1/30/1999 12:46:00 PM
From: Ricky Rydell	Read Replies (1) \| Respond to of 9523

After that huge posting and all that text what you are saying is that Pfizer has an excellent marketing machine, market share, and many, many products coming down the pipe. I agree. It is a good stock and a good company.

To: BigKNY3 who wrote (6876)	1/31/1999 7:49:00 PM
From: Mick Mørmøny	Respond to of 9523

Re: But the danger is that it can take years to complete a rollout, handing generic companies and competitors valuable time to come up with me-too products. -- Boston Consulting Group It takes about 12 years on average for a drug to find its way through the lab to your medicine chest. Here's why: 1. Preclinical Testing: Lab testing and animal studies for safety. 2. Clinical trials, Phase I: Human testing on volunteers for safety and dosage. 3. Clinical Trials, Phase II: Testing for effectiveness on people with the disease. 4. Clinical Trials, Phase III: Testing in hospitals for efficacy and adverse reactions. 5. New Drug Application: Company files the data to demonstrate safety and effectiveness. 6. FDA Approval: Company must continue to submit any cases of adverse reaction. So does every drug have a generic counterpart? No. Generally, when brand-name drugs are first introduced, they are patent-protected for 17 years. During this time, only that one brand of drug is allowed on the market, unless the manufacturer decides to allow others. When the patent expires, other drug companies can then introduce competitive generic versions of the brand-name product.